### **Are depot anti-psychotics associated with longer**

<sup>2</sup> persistence in treatment compared with oral

- antipsychotics among patients with Schizophrenia?
- 4
- 5

#### 6 ABSTRACT

Aim: Non-adherence with antipsychotics is associated with poor outcomes in patients with schizophrenia. It was anticipated that drop-out from treatment due to non-compliance with oral antipsychotics could be abated with the use of depot antipsychotics. However previous studies are divergent regarding the association between persistence in treatment and the use of depot antipsychotics. This study aimed to compare treatment persistence among out-patients with schizophrenia receiving depot versus oral antipsychotics in Lagos, Nigeria.

Methodology: Relevant clinical data of out-patients with schizophrenia (n=160) were retrieved one year post-hospitalisation at a public psychiatric facility in Nigeria. Treatment persistence (time to all cause treatment discontinuation) among the cohort of patients was determined using the Kaplan-Meier Survival analyses. Persistence in treatment between patients receiving depot versus oral antipsychotic medications alone was compared using the log rank test.

18 **Results**: Nearly half (49.1%) of the cohort dropped out of treatment within one month of discharge, 19 while 18.2% persisted for one year. There was no significant difference (p=0.727) in the mean 20 duration of treatment persistence between patients receiving depot antipsychotics (17.4(±2.4) weeks), 21 and those receiving oral medications alone (19.4 (±2.2) weeks).

22

Conclusion: There is a high rate of drop-out from treatment among patients with schizophrenia, after discharge from in-patient care. Prescription of depot medications was not associated with longer persistence treatment in the studied cohort. This finding highlights the need to develop interventions to facilitate treatment persistence among patients with schizophrenia.

27

#### 28 1. INTRODUCTION

Schizophrenia is a severe disorder that interferes with functioning in multiple neuro-psychological domains including cognition, perception, and thought systems. Schizophrenia usually runs a chronic course which may be punctuated by intermittent periods of remission and relapse. Anti-psychotics are the mainstay in the treatment of schizophrenia, and are effective in the treatment of psychotic symptoms, as well as reducing the risk of relapse and re-hospitalisation [1, 2].

Despite the availability and effectiveness of anti-psychotics in the therapy of schizophrenia, research has consistently shown a low rate of treatment adherence or persistence in treatment. More than half of patients with schizophrenia discontinue anti-psychotics treatment within the first year of onset of treatment [3-5]. Non-persistence in treatment has dire clinical, social and public health implications including increased risk of relapse, re-hospitalisation, increased burden on emergency services, suicide and mortality [6-10].

In terms of efficacy in the treatment of the positive and negative symptoms of schizophrenia, evidence has shown that depot antipsychotics are at least at par with their oral equivalent, if not better [11-17]. In addition, depot formulations are expected to address non-compliance attributable to forgetting to use medications or lack of insight; which are quite common among patients with schizophrenia [15-17]. On the flip side, pain at injection sites, perception of coercion or lack of autonomy and stigma may not favour adherence with depot anti-psychotics [15-17].

46 With the advent of long acting injections, it was envisaged that these medications would facilitate 47 monitoring of treatment compliance, thereby guaranteeing administration of medications and 48 transparency of adherence [15-17]. Consequently, it was anticipated that this would allow the 49 clinicians to be promptly alerted and intervention instituted if patients fail to receive their depot 50 medications. The anticipation that depot antipsychotics would guarantee treatment adherence and 51 persistence in treatment has not been consistently substantiated by extant research evidence. While 52 several authors reported a longer persistence in treatment or better adherence with depot versus oral 53 antipsychotics in naturalistic samples, results of randomised control trials and meta-analyses 54 contradict these findings [15-22].

55 A few studies have reported high rates of non-compliance with medications or clinic appointments 56 among patients with chronic psychiatric disorders in sub-saharan Africa [23-28]. However, there is 57 dearth of evidence on treatment adherence or treatment persistence with depot versus oral anti-58 psychotics in Africa. A retrospective study conducted at a tertiary mental health service in Nigeria 59 found that less than a quarter of patients with schizophrenia persisted in treatment for one year [27]. 60 A more recent study conducted at a psychiatric hospital in south-west Nigeria reported similar findings 61 [28]. However, these studies did not investigate the relationship between route of administration of 62 medications and treatment persistence. The current study aimed to compare persistence in treatment 63 between patients with schizophrenia receiving depot antipsychotics and those receiving oral 64 antipsychotics after discharge from in-patient care to out-patient clinic in a Nigerian psychiatric 65 hospital.

66

#### 67 **METHODOLOGY**

The methodology of the current study has been previously described by the author in a recent study comparing treatment persistence among patients with schizophrenia receiving first-generation versus second generation oral antipsychotics [28]. The study was conducted at a public tertiary mental health care facility, Federal Neuro-Psychiatric Hospital Yaba Lagos, located in south-West Nigeria. The hospital has an in-patient facility with 500 beds and out-patient clinics attended by more than a thousand patients weekly. The study design was a retrospective cohort study.

74 Patients with schizophrenia hospitalised over a six-month period between January and June 2012 75 and subsequently discharged to attend follow-up appointment at the out-patient clinic constituted the 76 study population. As part of a larger study of clinical outcomes in patients with schizophrenia, the 77 medical records were reviewed between October and December 2013 to assess persistence in 78 treatment over a period of one year after discharge from in-patient care to out-patient clinic. Inclusion 79 criteria for recruitment into the sample included case-notes with documented diagnoses of 80 schizophrenia by consultant psychiatrists according to the ICD-10 diagnostic criteria [29]. Patients 81 less than 18 years and greater than 65 years were excluded from the sample.

Data retrieved for each patient included socio-demographic characteristics, clinical diagnosis, number of episodes of illness, number of psychiatric hospitalisations, prescribed class and route of administration of anti-psychotic medications (e.g. typical or atypical and depot versus oral), and attendance of out-patient clinic appointment/prescription refill over a period of one year after discharge from the hospital (treatment persistence).

Treatment persistence was defined as the time to all-cause treatment discontinuation and calculated as the total number of consecutive weeks from the date of hospital discharge to the onset of the first treatment gap of > 14 consecutive days. Similar definition has been used by previous researchers on this subject [4, 30]. Treatment gap commenced from the date of the missed clinic appointment/ prescription refill. Research indicates that medical records of clinic attendance/prescription refill highly correlate with pharmacy refill and these indices are valid indirect measures of treatment adherence [4, 31-32].

94 Routinely, the standard protocol at the facility where the study was conducted is such that patients 95 with schizophrenia receive take-home prescriptions for anti-psychotic medications, which are 96 collected from the hospital pharmacy before discharge. The quantities of drugs prescribed are 97 sufficient until the date of the scheduled follow-up appointment at the out-patient clinic. At each 98 follow-up visit, prescriptions are refilled after consultation and documented in the clinical records. All 99 the patients on depot medications were on typical (first-generation) depot antipsychotics such as 100 fluphenazine, depixol and clopixol in addition to oral antipsychotics. The oral antipsychotics regularly 101 available in the hospital at the time of the study included olanzapine, risperidone, clozapine, 102 chlorpromazine, trifluoperazine and haloperidol. Institutional approval was obtained from the 103 Research and Ethical Committee.

**Statistical Analysis**: Data was analysed with IBM- SPSS (version 20). Kaplan-Meier Survival analyses was used to determine the major outcome of interest; persistence in treatment. Participants who had not dropped out of treatment before the end of the one year period of review were right censored. The log-rank test was used to compare treatment persistence between patients receiving depot versus oral antipsychotics.

109 **2. RESULTS** 

110 The current sample consisted of 160 patients with schizophrenia discharged from in-patient to out-111 patient clinic at a public psychiatric Hospital in Nigeria. There were more females (59.4%) than males, 112 and less than one third (31.3%) were married. The mean age of the patients was 38.7 (±11.4) years 113 (Table 1). The majority attained secondary (35%) or tertiary (43%) levels of education, but only 36.5% 114 were employed. Among the cohort that constituted the study sample, the median number of episodes 115 of schizophrenia was 2, while the median number of psychiatric hospitalisation was 1. Depot 116 antipsychotics were prescribed for 48.1% of the patients, while 51.9% received oral antipsychotics 117 alone.

119		N= 160	
120	Variable	n	(%)
121			
122	Gender		
123	Male	65	(40.6)
124	Female	95	(59.4)
125	Marital status		
126	Married	50	(31.3)
127	Single	110	(68.7)
128	Employment status		
129	Employed	58	(36.5)
130	Unemployed	102	(63.5)
131	Level of education		
132	No formal education	5	(3.1)
133	Primary	18	(11.3)
134	Secondary	56	(35.0)
135	Tertiary	69	(43.1)
136	*		
137			

118 Table 1: Socio-demographic characteristics of the patients in the sample


138

Based on the earlier defined criteria, only 50.9% of patients with schizophrenia persisted in treatment one month after discharge from the hospital. Subsequently, there was a gradual decline in persistence in treatment. By the end of the third and sixth month, 45.9% and 28.9% of the patients persisted in treatment respectively. Only 18.2% had not defaulted from treatment one year after discharge from the hospital.

144 The mean time to all cause treatment discontinuation calculated by the Kaplan-Meier survival analysis 145 (figure 1) indicated that the mean duration of treatment persistence among the patients was 18.5 146 (±1.6) weeks (95% C.I= 15.4-21.6). Among patients receiving depot antipsychotics, the mean duration 147 of treatment persistence was 17.4(±2.4) weeks (95% C.I= 12.8-22.1), while those receiving oral 148 medications alone had mean duration of treatment persistence of 19.4 (±2.2) weeks (95% C.I= 15.2-149 23.7). Using the log-rank (Mantel-cox) test, a comparison of the survival times between both groups of 150 patients revealed no statistically significant difference in treatment persistence (chi-square=0.122, 151 p=0.727).

#### 152 Figure1: Kapan-Meier survival analysis curve comparing treatment persistence between

153 patients using depot versus oral antipsychotics



#### Survival Functions

154

155

#### 156 **3. DISCUSSION**

This study compared persistence in treatment between out-patients with schizophrenia receiving depot antipsychotic medications versus those receiving oral antipsychotics alone, following discharge from a tertiary psychiatric care facility in south-west Nigeria. The socio-economic profile of the patients in this cohort is consistent with the pattern of impairment in social and occupational domains typically seen in patients with schizophrenia [33].

Within one month of discharge from in-patient care, nearly half of the sample had dropped out of treatment, and by the end of the third month post-discharge, only 46% persisted in treatment. A study of post-discharge treatment adherence among patients discharged from a Psychiatric Hospital in Nigeria similarly reported that only 50.6% of the patients were persistent in treatment until the 3<sup>rd</sup> month post-hospitalisation [24]. The current study also found that about 4 out of 5 patients with

schizophrenia had dropped out of treatment within one year of discharge to out-patient care. This finding is consistent with that reported among patients with first episode schizophrenia in south-west Nigeria, where only 1 out of 4 patients persisted in treatment for one year [27]. Research evidence from other parts of the globe including North America, Europe and Asia have also demonstrated low rates of persistence in treatment among patients with schizophrenia [4, 5, 34-38].

172 The current study found no significant difference in treatment persistence between patients receiving 173 depot and oral antipsychotics. Previous research on this subject demonstrated divergent findings. 174 While some authors reported that patients with schizophrenia or first episode psychosis treated with 175 depot antipsychotics had significantly longer time to discontinuation of treatment compared to patients 176 on oral antipsychotics [15, 17, 39-43] others found no association between treatment persistence and 177 route of administration of antipsychotics [15,17-22]. The largest meta-analysis of randomised 178 controlled trial on this subject comparing depot versus oral medication among patients with 179 schizophrenia found no significant difference [16, 22]. It was envisaged that long acting injections 180 would facilitate monitoring of treatment compliance, thereby guaranteeing administration of 181 medications and transparency of adherence [16]. Consequently, it was anticipated that this would 182 allow the clinicians to be promptly alerted and intervention instituted if patients fail to receive their 183 depot medications.

184 In the current study, patients who received depot medication prescriptions had shorter persistence in 185 treatment compared with patients receiving oral antipsychotics alone. Studies have shown that 186 patients may perceive long acting anti-psychotic injections as coercive and stigmatizing, and such 187 attitudes could consequently lead to non-adherence [44]. Furthermore, the injections are associated 188 with tissue irritation and pain which may discourage persistent compliance. The low rate of treatment 189 persistence among patients receiving depot antipsychotics may also be attributed to the fact that 190 patients selected by clinicians to receive depot medication prescription in the first place may be 191 patients perceived by clinicians to have high risk of drop-out from treatment. Evidence indicates that 192 clinicians are more likely to prescribe depot form of medications to patients with past history of poor 193 adherence with oral medications and those with a past history of relapse [16, 45]. On the other hand, 194 patients with high level of insight and good therapeutic alliance are more likely to receive prescriptions 195 of oral medications than long acting injections.

196 The high rate of drop-out from treatment, even among patients who received long acting anti-197 psychotic injection prescription is a worrisome finding because of the associated increased risk of 198 relapse, re-hospitalisation and burden of treatment [6-10]. This is particularly important in a low-199 resourced country where community based mental health resources are scarce, and prescription of 200 long-acting injections to patients perceived to have a high risk of default may be one of the few or 201 perhaps the only feasible 'intervention' relied on to facilitate persistence in treatment. This finding 202 highlights the need for other interventions to facilitate persistence in treatment among patients with 203 schizophrenia. Patients with schizophrenia and their informal caregivers must be educated on the 204 chronic nature of the disease and the consequences of discontinuation of treatment. Furthermore, 205 advocacy efforts must be stepped up in order to ensure that barriers to treatment persistence such as 206 poor access to mental health services, poor mental health care financing, non-integration of mental 207 health into primary care and stigma are addressed by policy makers [23, 46, 47].

208 In comparing this study with previous research on this subject, it is important to note that the patients 209 receiving depot medications were also using oral anti-psychotics concomitantly. The current study is 210 limited by its retrospective design which precludes face to face interview with service users and 211 consequently information on the specific barriers to persistence in treatment. Furthermore, since most 212 mental health facilities in Nigeria accept patients without formal referrals, patients who appear to have 213 dropped out of treatment may have opted to continue treatment in another facility without 214 documentation. Finally data retrieved from health records may be limited by missing data and errors 215 of documentation. The major strength of the current study lies in the standardised approach used to 216 estimate treatment persistence, in consistence with previous research. Furthermore, the naturalistic 217 design of the study which bars the influence of the researcher, or any other form of inducement that 218 could preferentially facilitate treatment persistence in any of the study groups also adds to the 219 strength of the study.

#### 220 CONCLUSION

The current study found a high rate of drop-out from out-patient treatment among patients with schizophrenia post-hospitalisation. There was no significant difference in persistence in treatment between patients receiving long acting anti-psychotics injections and those receiving only oral

- antipsychotics. These findings highlight the need for interventions to minimise drop-out from treatment
- among patients with schizophrenia.

226 227 228 229	REFER	ENCES
230	1.	Wyat RJ. Neuroleptics and the natural course of schizophrenia. Schizophrenia Bulletin, 1991;
231		17 (2):325–351.
232	2.	Harrow M, Jobe TH, Grossman LS, Ghogari V, Faull RN. Lifetime antipsychotic treatment for
233		all schizophrenia patients? A 26-year evidence-based approach. Schizophrenia Bulletin,
234		2011; 37(1):1–342.
235	3.	Malan RD, Luchins DJ, Fichtner CG et al. Discontinuity of outpatient antipsychotic
236		pharmacotherapy: risperidone maintenance after hospitalization. J Pharm Technol. 2001; 17:
237		90-94.
238	4.	Ascher-Svanum H, Zhu B, Faries DE, Lacro JP, Dolder CR, Peng X. Adherence and
239		persistence to typical and atypical antipsychotics in the naturalistic treatment of patients with
240		schizophrenia. Patient Prefer Adherence. 2008;2:67–7
241	5.	Alene M, Wiese MD, Angamo MT et al. Adherence to medications for the treatment of
242		psychosis: rates and risk factors in an ethopian population. BMC Pharmacology and
243		toxicology. 2012; 12 (10):1-9.
244	6.	Thieda P, Beard S, Richter A, et al. An economic review of compliance with medication
245		therapy in the treatment of schizophrenia. Psychiatric Services. 2003; 54:508-16.
246	7.	Valenstein M, Copeland LA, Blow FC, et al. Pharmacy data identify poorly adherent patients
247		with schizophrenia at increased risk for admission. Med Care. 2002; 40:630-9.
248	8.	Gilmer TP, Dolder CR, Lacro JP, et al. Adherence to treatment with antipsychotic medication
249		and health care costs among Medicaid beneficiaries with schizophrenia. Am J Psychiatry.
250		2004; 161:692–9.
251	9.	Weiden PJ, Kozma C, Grogg A, et al. Partial compliance and risk of rehospitalization among
252		California Medicaid patients with schizophrenia. Psychiatric Services. 2004; 55:886-91.
253	10.	Cullen BA, Mc Ginty EE, Zhang Y et al. Guideline-concordant antipsychotic use and mortality
254		in schizophrenia. Schizophr Bull. 2013; 39 (5): 1159-68.
255	11.	Rosenheck RA, Krystal JH, Lew R, et al. Long-acting risperidone and oral antipsychotics in
256		unstable schizophrenia. New England Journal of Medicine. 2011; 364 (9):842-851.
257	12.	Adams CE, Fenton MKP, Quraishi S, David AS. Systematic meta-review of depot
258		antipsychotic drugs for people with schizophrenia. British Journal of Psychiatry. 2011; 179:
259		290–299.
260	13.	Leucht C, Heres S, Kane JM, Kissling W, Davis JM, Leucht S. Oral versus depot
261		antipsychotic drugs for schizophrenia-A critical systematic review and meta-analysis of
262		randomised long-term trials. Schizophrenia Research. 2011; 127 (1-3):83-92.

263 14. Schooler NR, Levine J, Severe JB. Prevention of relapse in schizophrenia. An evaluation of 264 fluphenazine decanoate. Archives of General Psychiatry. 1980; 37(1):16-24. 265 15. Zhornitsky S and Stip E. Oral versus Long acting injectable antipsychotics in the treatment of 266 schizophrenia and special populations at risk for treatment non-adherence: A systematic 267 Review. Schizophrenia Research and Treatment. 2012; Article ID 407171:1-12. 268 16. Brissos S, Veguilla MR, Taylor D, Balanza-Martinez V. The role of long-acting injectable 269 antipsychotics in schizophrenia: a critical appraisal. Therapeutic Advances in 270 Psychopharmacology.2014; 4(5): 198-219. 271 17. Kaplan G, Casoy J, Zummo J. Impact of long –acting injectable antipsychotics on medication 272 adherence and clinical, functional and economic outcomes of schizophrenia. Patient 273 Preference and Adherence. 2013; 7: 1171-1180. 274 18. Olfson M, Marcus SC, Ascher-Svanum H. Treatment of schizophrenia with long-acting 275 fluphenazine, haloperidol, or risperidone. Schizophrenia Bulletin. 2007; 33 (6): 1379-1387. 276 19. Rosenheck RA, Krystal JH, Lew R, et al. Long-acting risperidone and oral antipsychotics in 277 unstable schizophrenia. N Engl J Med. 2011;364 (9):842-851. 278 20. Haddad PM, Taylor M, Niaz OS. First-generation antipsychotic long-acting injections v oral 279 antipsychotics in schizophrenia: systematic review of randomised controlled trials and 280 observational studies. Br J Psychiatry Suppl. 2009; 52: S20-S28. 281 21. Fusar-Poli P, Kempton MJ, Rosenheck RA. Efficacy and safety of second-generation long-282 acting injections in schizophrenia: a meta-analysis of randomized-controlled trials. Int Clin 283 Psychopharmacol. 2013; 28(2):57-66. 284 22. Kishimoto T, Robenzadeh A, Leucht C, et al. Long-acting injectable vs oral antipsychotics for 285 relapse prevention in schizophrenia: a meta-analysis of randomized trials. Schizophr Bull. 286 2014; 40: 192-213. 287 23. Adelekan MO, Ogunlesi AO. Defaulting at a Nigerian National Neuro-psychiatric Hospital. 288 Psychiatric Bulletin. 1990; 14 (7): 403-405. 289 24. Adeponle AB, Thombs BD, Adelekan ML, Kirmayer, L.J. Family participation in treatment, 290 post-discharge appointment and medication adherence at a Nigerian Psychiatric Hospital. 291 British Journal of Psychiatry. 2009; 194, 86-87. 292 25. Adewuya AO, Owoeye OA, Erinfolami AR, et al. Prevalence and correlates of poor 293 medication adherence amongst psychiatric outpatients in southwestern Nigeria. Gen Hosp 294 Psychiatry. 2009; 31 (2): 167-74. 295 26. Adeosun II, Ogun OC, Ijarogbe TG, et al. Pattern of Defaulting from a Nigerian Child and 296 Adolescent Psychiatric Clinic. Nigerian Journal of Psychiatry. 2012; 10 (3), 13-17. 297 27. Esan O. Persistence in treatment for one year among patients in Nigeria with first episode 298 schizophrenia. Psychiatric Services. 2014; 65 (9), 1174-1176. 299 28. Adeosun II. Treatment persistence associated with typical versus atypical antipsychotics 300 among patients with schizophrenia. British Journal of Pharmaceutical Research. 2016; 10 (4), 301 1-8. 302 29. World Health Organization. International Classification of Diseases (ICD-10). Geneva. 1992.

303	30. Ascher-Svanum H, Zhu B, Faries D, et al. Time to discontinuation of atypical versus typical
304	antipsychotics in the naturalistic treatment of schizophrenia. BMC Psychiatry. 2006b; 6:8.
305	31. Dolder CR, Lacro JP, Dunn LB, et al. Antipsychotic medication adherence: is there a
306	difference between typical and atypical agents? Am J Psychiatry. 2002; 159:103-8.
307	32. Svarstad BL, Shireman TI, Sweeney JK. Using drug claims data to assess the relationship of
308	medication adherence with hospitalization and costs. Psychiatr Services. 2001; 52:805–11.
309	33. Kessler TC, Wai O, Demler, Walters EE. Prevalence, severity, and comorbidity of 12-month
310	DSM-IV disorders in the national comorbidity survey replication. Archives of General
311	Psychiatry. 2005; 62 (6): 617–627.
312	34. Fenton WS, Blyler CR, Heinssen RK: Determinants of medication compliance in
313	schizophrenia: empirical and clinical findings. Schizophr Bull. 1997; 23:637-65
314	35. Young JL, Zonana HV, Shepler L: Medication noncompliance in schizophrenia: codification
315	and update. Bull Am Acad Psychiatry Law. 1986; 14:105–122
316	36. Mitchell AJ and Selmes T. Why don't patients attend their appointments? Maintaining
317	engagement with psychiatric services. Advances in Psychiatric treatment. 2007; 13: 423-434.
318	37. Kreyenbuhl J, Slade EP, Medoff DR, et al. Time to discontinuation of first and second-
319	generation antipsychotic medications in the treatment of schizophrenia. Schizophrenia Res.
320	2011; 131 (1-3): 127-32.
321	38. Valenstein M, Ganoczy D, McCarthy JF, et al. Antipsychotic adherence over time among
322	patients receiving treatment for schizophrenia: a retrospective review. J Clin Psychiatry. 2006;
323	67 (10): 1542-50.
324	39. Zhu B, Ascher-Svanum H, Shi L, Faries D, Montgomery W, Marder SR. Time to
325	discontinuation of depot and oral first-generation antipsychotics in the usual care of
326	schizophrenia. Psychiatric Services. 2008; 59 (3): 315–317.
327	40. Kim B, Lee SH, Choi TK et al. Effectiveness of risperidone long-acting injection in first-
328	episode schizophrenia: in naturalistic setting. Progress in Neuro-Psychopharmacology and
329	Biological Psychiatry. 2008; 32(5):1231–1235.
330	41. Olivares JM, Rodriguez-Morales A, Diels J, Povey M, Jacobs A, Zhao Z. Long-term outcomes
331	in patients with schizophrenia treated with risperidone long-acting injection or oral
332	antipsychotics in Spain: results from the electronic Schizophrenia Treatment Adherence
333	Registry (e-STAR). Eur Psychiatry. 2009; 24(5):287–296.
334	42. Brnabic AJ, Kelin K, Ascher-Svanum H, Montgomery W, Kadziola Z, Karagianis J. Medication
335	discontinuation with depot and oral antipsychotics in outpatients with schizophrenia:
336	comparison of matched cohorts from a 12-month observational study. Int J Clin Pract. 2011;
337	65(9):945–953.
338	43. Shi L, Ascher-Svanum H, Zhu B, Faries D, Montgomery W, Marder SR. Characteristics and
339	use patterns of patients taking first-generation depot antipsychotics or oral antipsychotics for
340	schizophrenia. Psychiatr Services. 2007; 58(4):482–488.
341	44. Jaeger M. and Rossler W. Attitudes towards long-acting depot antipsychotics: a survey of
342	patients, relatives and psychiatrists. Psychiatry Research. 2010; 175: 58–62.

343	45. Samalin L, Charpeaud T, Blanc O, Heres S, Llorca P. Clinicians' attitudes toward the use of
344	long-acting injectable antipsychotics. J Nerv Ment Dis. 2013; 201: 553-559
345	46. Klecha D, Barke A, Gureje O. Mental health care in developing countries: the example of
346	Nigeria. Nervencrzt. 2004; 75 (11): 1118-1122.
347	47. Adeosun II, Adegbohun A, Jeje O, .Adewumi A. Experiences of Discrimination by people with
348	Schizophrenia in Lagos Nigeria. Journal of Public Mental Health. 2014; 13(4):189-196
349	
350	
351	